Several clear clinical scenarios exist for MBL2 replacement trials, including MBL deficiency in cases of recurrent childhood infection, prophylaxis against sepsis following chemotherapy, and rapidly progressive cystic fibrosis. This evidence concerns the gene MBL2 and hyperinsulinemic hypoglycemia, familial, 4.